FDA transparency comments through Nov. 6
This article was originally published in The Rose Sheet
Executive Summary
FDA will accept comments on its transparency initiative through Nov. 6, after which time the Transparency Task Force will conduct its second public meeting. The agency posts initiative information on its transparency Web site, which will operate while the comment docket is open. The task force consists of Principal Deputy Commissioner Josh Sharfstein, the directors of each of FDA's centers, acting Associate Commissioner for Regulatory Affairs Michael Chappell, acting Chief Counsel Michael Landa and acting Chief Scientist Jesse Goodman. Attorney Afia Asamoah, special assistant to Sharfstein, helps staff the task force, and policy analyst Erik Mettler oversees the blog. Commissioner Margaret Hamburg appointed the task force to identify how to improve communication and better explain agency decisions (1"The Rose Sheet" June 15, 2009)
You may also be interested in...
FDA Task Force Created To Promote Transparency, Solicit Public Input
FDA's formation of an internal Transparency Task Force is a savvy move that allows agency leaders to begin making good on their pledge to enhance openness while having six months before them to decide how exactly that will be done
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.